Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CLLS)
NASDAQ:CLLS
Top Page
Cellectis SA
(NASDAQ:CLLS)
57Neutral
Positive Factors
Cash Reserves
Cellectis had ~$264M in cash which in combination with potential milestone payments is expected to fund the business into 2027.
Financial Performance
Cellectis reported 3Q24 revenue of $18.1M vs. analyst's estimate of $11.2M.
Strategic Partnerships
The AZN partnership is progressing, initially focused on three programs with an option to expand to ten in total.
Negative Factors
Deprioritization
The development of UCART123 in acute myeloid leukemia (AML) was deprioritized.
Operational Costs
Cellectis reported a 3Q24 update with opex of $28.8M and a quarter-end cash balance of $264M, up from $165M at YE2023.
Cellectis SA (CLLS) vs. S&P 500 (SPY)
Market Cap
$118.22M
Dividend YieldN/A
Average Volume (3M)98.26K
Price to Earnings (P/E)―
Beta (1Y)3.61
Revenue Growth5397.35%
EPS Growth77.93%
CountryUS
Employees216
SectorHealthcare
Sector Strength60
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.17
Shares Outstanding72,093,636
10 Day Avg. Volume53,877
30 Day Avg. Volume98,257
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.53
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.50Price Target Upside243.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cellectis SA Business Overview & Revenue Model
Company DescriptionCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
How the Company Makes MoneyCellectis makes money primarily through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and potential royalties based on the successful development and commercialization of products stemming from its gene-editing technologies. Additionally, Cellectis may generate revenue by advancing its own proprietary pipeline of CAR-T cell therapies through clinical trials, with the potential of achieving regulatory approvals and subsequent commercialization. The company's business model leverages its intellectual property and technological expertise in gene editing to create value and establish revenue streams from both collaborative and independent development efforts.
Cellectis SA Financial Statement Overview
Summary
Cellectis SA shows promising revenue growth but struggles with profitability and efficiency. The balance sheet reflects moderate leverage but low returns on equity. Despite improved cash flow, the company faces challenges in achieving consistent profitability.Income Statement
The company's revenue increased significantly in the TTM, but it operates at a loss with a negative net profit margin. The gross profit margin is healthy, but the EBIT and EBITDA margins are negative, reflecting operational inefficiencies and high expenses relative to revenue.35
Negative
Balance Sheet
The debt-to-equity ratio is moderate, showing balanced leverage. However, the company has negative net income, resulting in a negative ROE, which is concerning. The equity ratio indicates a reasonable level of equity financing.40
Negative
Cash Flow
The company has positive operating cash flow and free cash flow in the TTM. This is an improvement from prior periods, but the free cash flow to net income ratio is negative due to persistent net losses, indicating cash flow generation challenges.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 41.51M | 755.00K | 19.17M | 73.95M | 73.95M | Gross Profit |
| 41.51M | 18.00K | 17.40M | 37.67M | 37.67M | EBIT |
| -59.55M | -106.63M | -89.67M | -85.44M | -85.44M | EBITDA |
| -9.46M | -92.64M | -76.38M | -86.46M | -34.68M | Net Income Common Stockholders |
| -36.76M | -101.06M | -98.69M | -86.28M | -72.57M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 260.31M | 203.81M | 97.70M | 186.13M | 268.24M | Total Assets |
| 383.54M | 334.27M | 261.22M | 382.08M | 469.47M | Total Debt |
| 91.46M | 92.85M | 82.85M | 102.24M | 111.30M | Net Debt |
| -51.79M | -43.85M | -14.85M | -83.90M | -156.94M | Total Liabilities |
| 252.51M | 249.57M | 135.28M | 145.60M | 160.63M | Stockholders Equity |
| 131.03M | 84.69M | 117.97M | 221.29M | 275.57M |
| Cash Flow | Free Cash Flow | |||
| 19.15M | -25.82M | -89.89M | -124.31M | -126.52M | Operating Cash Flow |
| 22.99M | -24.75M | -87.44M | -104.56M | -80.26M | Investing Cash Flow |
| -102.81M | -15.51M | -2.76M | 7.28M | -54.34M | Financing Cash Flow |
| 89.11M | 82.86M | 1.15M | 47.52M | 27.32M |
Cellectis SA Technical Analysis
Positive
1.60
Price Trends
1.35
Positive
1.50
Positive
1.78
Negative
Market Momentum
0.08
Negative
64.87
Neutral
80.85
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLLS, the sentiment is Positive. The current price of 1.6 is above the 20-day moving average (MA) of 1.45, above the 50-day MA of 1.35, and below the 200-day MA of 1.78, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 64.87 is Neutral, neither overbought nor oversold. The STOCH value of 80.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLLS.
Cellectis SA Risk Analysis
Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cellectis SA Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $118.22M | ― | -34.08% | ― | 5397.35% | 77.93% | |
52 Neutral | $5.35B | 3.83 | -41.61% | 2.85% | 17.10% | 1.22% | |
39 Underperform | $148.30M | ― | -31.94% | ― | ― | 30.76% | |
39 Underperform | $174.10M | ― | -25.95% | ― | ― | ― | |
38 Underperform | $81.84M | ― | -47.99% | ― | -71.01% | -14.04% | |
33 Underperform | $137.28M | ― | -98.10% | ― | -58.64% | -40.05% | |
33 Underperform | $82.58M | ― | -94.52% | ― | ― | 2.98% |
* Healthcare Sector Average
Performance Comparison
CLLS
Cellectis SA
1.60
-1.50
-48.39%
EDIT
Editas Medicine
1.54
-4.14
-72.89%
NKTX
Nkarta
1.98
-4.82
-70.88%
FDMT
4D Molecular Therapeutics
3.57
-23.23
-86.68%
VOR
Vor Biopharma
0.60
-1.16
-65.91%
CRBU
Caribou Biosciences
0.86
-2.87
-76.94%
Cellectis SA Earnings Call Summary
Earnings Call Date:Mar 13, 2025
(Q4-2024)
| % Change Since: 24.03%|
Next Earnings Date:May 07, 2025
Earnings Call Sentiment Positive
The earnings call reflected a positive outlook for Cellectis, highlighted by strategic collaborations, strong financial positioning, and advancements in clinical trials. Challenges include ongoing arbitration with Servier and patient enrollment progress, but these are outweighed by the company's achievements.Q4-2024 Updates
Positive Updates
Strategic Collaboration with AstraZeneca
Cellectis announced the start of three research and development programs under its collaboration with AstraZeneca, including allogeneic CAR T for hematological malignancies, solid tumors, and an in vivo gene therapy for a genetic disorder. AstraZeneca also completed an additional equity investment of $140 million in Cellectis.
Financial Stability and Cash Runway
Cellectis drew down the last tranches of a €40 million credit facility with the European Investment Bank and reported that their cash runway allows operations to be funded into mid-2027. As of December 31, 2024, the company had $264 million in cash, cash equivalents, and fixed term deposits, up from $156 million the previous year.
FDA and European Commission Designations
The FDA granted Orphan Drug Designation and Rare Pediatric Disease status to UCART22, and the European Commission granted Orphan Drug Designation for the treatment of relapse or refractory acute lymphoblastic leukemia.
Advancements in Clinical Trials
Cellectis expects to present Phase 1 data for UCART22 and UCART20x22 in 2025, with plans to open Phase 2 studies in Q4 2025. Recruitment for the BALLI-01 study evaluating UCART22 has progressed well.
Positive Financial Performance
Thanks to the AstraZeneca collaboration, $47 million were received up to year-end 2024, including $22 million from development milestones.
Promising Innovation in CAR T Strategies
Cellectis showcased promising CAR T strategies utilizing TALEN gene editing technology, with preclinical data presented at major conferences and publications in scientific journals.
Negative Updates
Servier Arbitration
There is ongoing arbitration with Servier, although specific details remain undisclosed.
Challenges in Patient Enrollment
Enrollment for the NATHALI-01 study of UCART20x22 in relapsed or refractory non-Hodgkin's lymphoma continues, but specific challenges or delays in enrollment were not detailed.
Company Guidance
In the recent Cellectis earnings call for fiscal year 2024, the company provided guidance on several key metrics. Cellectis announced that its cash runway is now extended to mid-2027, thanks to an additional equity investment of $140 million from AstraZeneca, which now owns approximately 44% of Cellectis' share capital and 30% of voting rights. The company also reported that it received $47 million under its collaboration with AstraZeneca, including $25 million upfront and $22 million from development milestones. Cellectis' cash, cash equivalents, and financial assets increased to $264 million as of December 31, 2024, compared to $156 million in the previous year. This increase is attributed to the equity investment, $20 million from the European Investment Bank credit facility, and revenue from partnerships, offset by operational expenses. The company expects to present Phase 1 data for UCART22 and UCART20x22 in 2025 and continues to advance its core clinical trials and collaboration with AstraZeneca.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.